Meridian Bioscience Inc (VIVO, Financial)(30-Year Financial) files //www.sec.gov/Archives/edgar/data/794172/000119312521337663/0001193125-21-337663-index.htm'' rel='nofollow' target='_blank'>its latest 10-K with SEC for the fiscal year ended on September 30, 2021.
For the last quarter Meridian Bioscience Inc reported a revenue of $76.2 million, compared with the revenue of $64.15 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $317.9 million, an increase of 25.3% from last year. For the complete 30-year financial data, please go here.. For the last five years Meridian Bioscience Inc had an average revenue growth rate of 9.1% a year.
The reported diluted earnings per share was $1.62 for the year, an increase of 51.4% from previous year. Over the last five years Meridian Bioscience Inc had an EPS growth rate of 18.8% a year. The Meridian Bioscience Inc enjoyed an operating margin of 29.1%, compared with the operating margin of 23.5% a year before. The 10-year historical median operating margin of Meridian Bioscience Inc is 26.82%. The profitability rank of the company is 8 (out of 10).
At the current stock price of $21.26, Meridian Bioscience Inc is traded at 21.9% discount to its historical median P/S valuation band of $27.22. The P/S ratio of the stock is 2.94, while the historical median P/S ratio is 3.94. The stock gained 12.63% during the past 12 months.
For the complete 20-year historical financial data of VIVO, click here.
